1. Home
  2. AZZ vs NAMS Comparison

AZZ vs NAMS Comparison

Compare AZZ & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AZZ Inc.

AZZ

AZZ Inc.

HOLD

Current Price

$146.58

Market Cap

4.3B

Sector

Industrials

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$35.30

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AZZ
NAMS
Founded
1956
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
4.1B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
AZZ
NAMS
Price
$146.58
$35.30
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$141.80
$46.75
AVG Volume (30 Days)
320.3K
1.1M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
0.58%
N/A
EPS Growth
486.59
N/A
EPS
1.72
N/A
Revenue
$1,061,817,000.00
N/A
Revenue This Year
$7.03
$17.96
Revenue Next Year
$4.25
$540.65
P/E Ratio
$81.91
N/A
Revenue Growth
14.53
N/A
52 Week Low
$92.98
$20.53
52 Week High
$162.20
$42.21

Technical Indicators

Market Signals
Indicator
AZZ
NAMS
Relative Strength Index (RSI) 47.29 57.72
Support Level $131.08 $33.83
Resistance Level $151.67 $37.27
Average True Range (ATR) 6.45 1.74
MACD -1.72 0.42
Stochastic Oscillator 38.24 71.19

Price Performance

Historical Comparison
AZZ
NAMS

About AZZ AZZ Inc.

AZZ Inc is a provider of galvanizing and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of AZZ Metal Coatings, AZZ Precoat Metals, and AZZ Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company operates in the United States and Canada.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: